Comparative Pharmacology
Head-to-head clinical analysis: GYNOREST versus PROVERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNOREST versus PROVERA.
GYNOREST vs PROVERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gynorest (dydrogesterone) is a synthetic progestogen that binds to the progesterone receptor with high selectivity, inducing conformational changes that promote transcription of progesterone-responsive genes. It has no androgenic, estrogenic, or corticosteroid activity, and does not inhibit ovulation.
Provera (medroxyprogesterone acetate) is a progestin that binds to progesterone receptors, suppressing gonadotropin secretion, inhibiting endometrial growth, and inducing secretory changes in the endometrium. It also has antigonadotropic effects by reducing LH and FSH release from the pituitary.
100 mg orally twice daily for 5-10 days or 300 mg orally once daily for 6-12 days.
Oral: 5-10 mg daily for 5-10 days for secondary amenorrhea; 5-10 mg daily for 12-14 days per cycle in combination with estrogen for endometrial hyperplasia; 400-1000 mg/day IM monthly for endometriosis.
None Documented
None Documented
Terminal elimination half-life is approximately 16-20 hours; supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life is approximately 12-17 hours for medroxyprogesterone acetate (oral). With depot intramuscular injection, the half-life is extended to approximately 50 days due to slow absorption from the injection site.
Renal: 50-80% as metabolites; Fecal: 20-50% as metabolites; Biliary excretion contributes to fecal elimination.
Renal (50-60% as metabolites), biliary/fecal (30-40%). Less than 1% excreted unchanged.
Category C
Category C
Progestin
Progestin